[Retracted] Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

Table 1

Expression of MMP-2 and VEGF after RZD treatment in SGC-7901 gastric cancers by real-time PCR.

Rosiglitazone (𝜇mol/L)	PPAR𝛾	MMP-2	VEGF
0	0.132127±0.045513	0.008912±0.000133	0.61132±0.078921
1	0.121878±0.034219	0.006003±0.000331^*	0.620255±0.054671
3	0.130134±0.0521137	0.005486±0.000541^*	0.60728±0.036799
5	0.137778±0.046222	0.005048±0.000346^*	0.599438±0.076541
10	0.141171±0.038741	0.001924±0.000189^*	0.624165±0.038966
20	0.143889±0.061237	0.001298±0.000267^*	0.604246±0.065679

^*Statistical significance (𝑃<.05 or higher degree of significance) versus vehicle-treated controls.